Thread by @Parsifaler

1) THE SPIKE PROTEIN: A PHARMACOLOGICAL “THERAPEUTIC” INTENDED TO INDUCE FATAL SYSTEMIC IRON DEPOSITION: DYSMETABOLIC HYPERFERRTINEMIA
First, please think about all we have read concerning COVID and its sequelae. Now please read this: Iron overload, irrespective of the underlying

2) etiology, has varying manifestations, depending on the organs affected by the excessive iron deposit. It may present as fatigue, skin color changes, abdominal pain, joint pain, irregular menstruation, infertility, impotence, irregular heart rhythm, heart failure, new-onset

3) diabetes or difficulty controlling established diabetes and elevation in liver enzymes.
And what of Hypoxia? Pathological? Certainly. Also, a possible adverse effect of a drug intended to induce fatal systemic iron deposition. While we have been scratching our heads trying to

4) figure out WHY the HYPOXIA seen in COVID is UNRELATED to our LUNGS, the spike protein has been going about its “merry” business of forcing ever more iron uptake and deposition.
Both the rate of erythropoiesis and hypoxia regulate iron absorption. Expression of ferroportin and

5) Dcytb are upregulated in hypoxia and in a hypotransferrinaemic mouse which has chronic anaemia due to defective erythropoiesis. Increased expression of these genes is likely to account for the increase in iron absorption.
What most people, including many doctors, do not

6) realize is that the inherited disease Hemochromatosis is not the only cause of Iron Overload and Iron Deposition. There is also another condition, which I believe we are observing: Dysmetabolic Hyperferritinemia.
Dysmetabolic hyperferritinemia, also known as insulin resistance

7) associated with iron overload, is a much more common disorder than recognized clinically by physicians.
While we have been dancing around the related CNS involvement and apparent neurodegeneration, let’s spell it out now, once and for all: Iron dyshomeostasis appears to be a

8) central factor in neurodegenerative conditions such as AD, PD, ALS, Huntington’s disease, and Friedreich’s ataxia. For decades, deposits of iron have been detected in brain lesions of patients with these neurodegenerative conditions. How iron accumulates in the

9) diseased/injured brain is not known, however, heme-bound iron that is derived from the circulation and non-heme bound iron (i.e., all iron not bound to heme protein) are both present in affected tissue. It is likely that the deposition of iron into the brain parenchyma in

10) these conditions is the result of either hemorrhage/microbleeds (i.e., heme-bound iron), damaged cells (i.e., neurons, oligodendrocytes and microglia), and myelin, inflammatory processes, degradation of erythrocytes and heme proteins, and/or dysregulation of important

11) iron-related proteins (e.g., ceruloplasmin, ferroportin).
We have witnessed just in the past few days the collapse of Astra Zeneca’s Director of Medicines and an Austrian MP live on camera. This can be attributed to Cardiac Iron Overload. Deposition of iron may occur in the

12) entire cardiac conduction system, especially the atrioventricular node. Complete atrioventricular block caused by iron depostion may need implacement of a permanent pacemaker [8]. Iron deposition in the cardiac tissue causes nonhomogenous electrical conduction and

13) repolarization with atrial and ventricular tachyarrhythmias. Chronic iron overload reduces CaV1.3-dependent L-type Ca2+ currents, resulting in bradycardia, altered electrical conduction, and atrial fibrillation. Paroxysmal atrial fibrillation is the most common arrhythmia

14) observed in patients with cardiac hemochromatosis. The prevalence of ventricular arrhythmias increases with left ventricular dilation and low LVEF. Sudden cardiac death may develop.
I believe iron is also being deposited in the pancreas, as the cases of new onset diabetes

15) indicates. Excessive iron storage sometimes causes diabetes in patients with hemochromatosis, a disease caused by iron overloading.
I believe all organs and systems of the body are being overloaded with iron by the Hepcidin/Iron Metabolism interference of the Spike Protein.

16) Studies must be conducted ASAP to determine post spike protein therapy iron biomarkers. I urge a pause on all spike protein therapies until such studies may be conducted. The cost of antibodies for a disease with a 99%+ survival rate may be the ultimate cost.

17) jstage.jst.go.jp/article/jmi/57…
biologydirect.biomedcentral.com/articles/10.11…
karger.com/article/fullte…
frontiersin.org/articles/10.33…
ncbi.nlm.nih.gov/labs/pmc/artic…
ncbi.nlm.nih.gov/labs/pmc/artic…
nature.com/articles/s4159…